Skip to main content
. 2012 Nov 27;12:562. doi: 10.1186/1471-2407-12-562

Table 5.

Cox analysis of metastasis-free survival (MFS) in the molecular subtypes (ER+/HER; ER-/HER2-; HER2+) according to Desmedt and co-workers [[31]]

  Mainz cohort(n=158) Rotterdam cohort(n=178) Transbig cohort(n=186) Combined cohorts(n=522)
A. Univariate analysis
ER+/HER2-
AURKA
P-value
0.011
<0.001
<0.001
<0.001
HR
1.786
2.916
2.174
2.100
95%-CI
1.144-2.787
2.022-4.206
1.491-3.171
1.700-2.594
 
Mainz cohort(n=23)
Rotterdam cohort(n=58)
Transbig cohort(n=59)
Combined cohorts(n=140)
ER-/HER2-
AURKA
P-value
0.497
0.808
0.924
0.993
HR
1.534
1.103
0.967
1.002
95%-CI
0.446-5.282
0.498-2.443
0.483-1.934
0.637-1.577
 
Mainz cohort(n=19)
Rotterdam cohort (n=50=)
Transbig cohort (n=35)
Combined cohorts (n=104)
 
HER2+
AURKA P-value
0.298
0.840
0.100
0.402
HR
2.303
1.088
0.439
0.785
95%-CI 0.478-11.091 0.481-2.461 0.165-1.171 0.446-1.382

AURKA is associated with MFS in the estrogen receptor positive but not in the estrogen receptor negative subtypes. A. Univarate analysis.